Decoding Your Pathology Report
At a Glance
A ccRCC pathology report details the specific characteristics of your kidney tumor after surgery. Key elements include the WHO/ISUP grade (1-4), TNM stage, and high-risk markers like tumor necrosis or sarcomatoid features. These details help your doctor determine your risk of recurrence.
After surgery, a pathologist examines the removed tissue to create a surgical pathology report. This document is the “gold standard” for understanding exactly what was happening inside the tumor and helps your medical team determine if you need additional treatment, such as adjuvant therapy (preventative treatment given after surgery to reduce the risk of return) [1].
The Grade: How Aggressive Are the Cells?
The grade of a tumor describes how different the cancer cells look compared to healthy kidney cells. A higher grade usually means the cancer is more aggressive.
- WHO/ISUP Grading System: This is the current standard, replacing the older Fuhrman system [2]. It ranks tumors from 1 to 4 based on the size and visibility of the nucleoli (the “command centers” inside the cell’s nucleus) [3].
High-Risk Features: Sarcomatoid and Rhabdoid
In some cases of ccRCC, the cells undergo a “shape-shift” into even more aggressive forms. If you see these terms on your report, it indicates a tumor that requires expert care from an oncologist [5].
- Sarcomatoid Differentiation: The cancer cells look like spindle-shaped cells found in muscle or bone cancer. This is a sign of a very aggressive tumor [6][7].
- Rhabdoid Differentiation: The cells look like large, specialized muscle cells. Like sarcomatoid features, this is linked to a higher risk of the cancer spreading [8][7].
Understanding Tumor Necrosis
Necrosis simply means “cell death.” In a tumor, necrosis happens when the cancer grows so fast that it outpaces its own blood supply, causing parts of the tumor to die [9]. While “dead” cells might sound like a good thing, the presence of necrosis in ccRCC is actually a marker that the tumor is growing rapidly and may be more likely to recur [10].
Staging: How Far Has It Reached?
Your report will also list a pathologic stage (labeled with a ‘p’, like pT1a). This is based on the TNM system [10]:
- T (Tumor): The size of the tumor and whether it has grown into nearby fat or the renal vein [11].
- N (Node): Whether the cancer has reached nearby lymph nodes [11].
- M (Metastasis): Whether the cancer has spread to distant organs [11].
Pathology Completeness Checklist
When reviewing your report, ensure these five critical elements are clearly stated:
- Histologic Subtype: It should explicitly say “Clear Cell Renal Cell Carcinoma” [12].
- WHO/ISUP Grade: A number from 1 to 4 [3].
- Pathologic Stage (pTNM): The size and extent of the tumor [10].
- Surgical Margins: Whether the edges of the removed tissue were clear of cancer cells [10].
- High-Risk Markers: Mention of Necrosis, Sarcomatoid, or Rhabdoid features [5][9].
Doctors often combine these factors into a “risk score” (like the Leibovich or SSIGN score) to help predict the chance of the cancer coming back and to decide if preventative immunotherapy is right for you [10][13].
Common questions in this guide
What does the WHO/ISUP grade mean on my kidney cancer pathology report?
Are sarcomatoid or rhabdoid features bad in ccRCC?
What does tumor necrosis mean?
How is the pathologic stage different from the clinical stage?
What are the SSIGN or Leibovich scores?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the final pTNM stage of my cancer, and does it involve any structures outside the kidney?
- 2.What is the WHO/ISUP grade of the tumor, and how much of the tumor was this grade?
- 3.Were sarcomatoid or rhabdoid features present? If so, does this change my eligibility for adjuvant therapy?
- 4.Are the surgical margins 'clear' or 'negative,' meaning all visible cancer was removed?
- 5.Based on my 'SSIGN' or 'Leibovich' score, what is my estimated risk of recurrence?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, et al.
The New England journal of medicine 2024; (390(15)):1359-1371 doi:10.1056/NEJMoa2312695.
PMID: 38631003 - 2
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.
Dagher J, Delahunt B, Rioux-Leclercq N, et al.
Histopathology 2017; (71(6)):918-925 doi:10.1111/his.13311.
PMID: 28718911 - 3
[The WHO/ISUP grading system for renal carcinoma].
Moch H
Der Pathologe 2016; (37(4)):355-60 doi:10.1007/s00292-016-0171-y.
PMID: 27271258 - 4
Grading of renal cell carcinoma.
Delahunt B, Eble JN, Egevad L, Samaratunga H
Histopathology 2019; (74(1)):4-17 doi:10.1111/his.13735.
PMID: 30565310 - 5
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(25)):2957-2995 doi:10.1200/JCO.22.00868.
PMID: 35728020 - 6
Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
Obeng RC, Arnold RS, Ogan K, et al.
International journal of urology : official journal of the Japanese Urological Association 2020; (27(9)):790-797 doi:10.1111/iju.14302.
PMID: 32638444 - 7
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
Singh RR, Murugan P, Patel LR, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(9)):1225-35 doi:10.1038/modpathol.2015.68.
PMID: 26111976 - 8
Molecular and Clinicopathological Profiling of Clear Cell Renal Cell Carcinoma with Rhabdoid Features: An Integrative Pathway-Based Stratification Approach.
Lu Z, Zhao Q, Xu H, et al.
Cancers 2025; (17(17)) doi:10.3390/cancers17172744.
PMID: 40940841 - 9
Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups.
Sirohi D, Chipman J, Barry M, et al.
Clinical genitourinary cancer 2022; (20(3)):e233-e243 doi:10.1016/j.clgc.2022.01.005.
PMID: 35125301 - 10
Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
Palumbo C, Perri D, Zacchero M, et al.
Urologic oncology 2022; (40(4)):167.e1-167.e7 doi:10.1016/j.urolonc.2021.11.025.
PMID: 35034803 - 11
CD47 Expression Predicts Unfavorable Prognosis in Clear Cell Renal Cell Carcinoma after Curative Resection.
Park H, Jee S, Bang S, et al.
Diagnostics (Basel, Switzerland) 2022; (12(10)) doi:10.3390/diagnostics12102291.
PMID: 36291980 - 12
Clear Cell Renal Cell Carcinoma: From Biology to Treatment.
Kase AM, George DJ, Ramalingam S
Cancers 2023; (15(3)) doi:10.3390/cancers15030665.
PMID: 36765622 - 13
P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.
Liu Z, Liu Y, Xu L, et al.
Cancer science 2015; (106(9)):1224-31 doi:10.1111/cas.12736.
PMID: 26179886
This page explains ccRCC pathology terminology for educational purposes only. Always consult your oncologist or pathologist to interpret your specific surgical pathology report.
Get notified when new evidence is published on Clear cell renal carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.